P A Fasching1, T Fehm2, S Kellner1, J de Waal3, M Rezai4, B Baier3, G Baake5, H-C Kolberg6, M Guggenberger7, M Warm8, N Harbeck9, R Würstlein9, J-U Deuker10, P Dall11, B Richter12, G Wachsmann13, C Brucker14, J W Siebers15, N Fersis16, T Kuhn17, C Wolf18, H-W Vollert19, G-P Breitbach20, W Janni21, R Landthaler22, A Kohls23, D Rezek24, T Noesslet25, G Fischer26, S Henschen27, T Praetz28, V Heyl29, T Kühn30, T Krauß31, C Thomssen32, S Kümmel33, A Hohn34, H Tesch35, C Mundhenke36, A Hein1, C Rauh1, C M Bayer1, A Jacob37, K Schmidt37, E Belleville38, P Hadji39, D Wallwiener40, E-M Grischke40, M W Beckmann1, S Y Brucker40. 1. Universitäts-Brustzentrum Franken, Frauenklinik, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen. 2. Universitäts-Frauenklinik Düsseldorf, Düsseldorf ; Universitätsfrauenklinik Tübingen, Tübingen. 3. Frauenklinik im Klinikum Dachau, Dachau. 4. Luisenkrankenhaus Düsseldorf, Düsseldorf. 5. Klinikum Pinneberg, Pinneberg. 6. Marienhospital Bottrop, Bottrop. 7. Klinikum Tuttlingen, Tuttlingen. 8. Brustzentrum, Universitäts-Frauenklinik Köln, Köln ; Brustzentrum, Klinken der Stadt Köln gGmbH Holweide, Köln. 9. Brustzentrum, Universitäts-Frauenklinik Köln, Köln ; Brustzentrum der Universität München, Frauenkliniken Großhadern und Maistrasse-Innenstadt, München. 10. Vinzenzkrankenhaus Hannover gGmbH, Hannover. 11. Frauenklinik, Klinikum Lüneburg, Lüneburg. 12. Elblandkliniken Meißen-Radebeul Standort Radebeul, Radebeul. 13. Kreiskrankenhaus Böblingen, Böblingen. 14. Universitätsklinik für Frauenheilkunde, Paracelsus Medizinische Privatuniversität, Nürnberg. 15. Frauenklinik des St. Josefsklinik Offenburg, Offenburg. 16. Frauenklinik, Klinikum Bayreuth GmbH, Comprehensive Cancer Center Erlangen-EMN, Bayreuth. 17. Karl-Olga-Krankenhaus, Stuttgart. 18. Medizinisches Zentrum Ulm, Ulm. 19. Klinikum Friedrichshafen, Friedrichshafen. 20. Städtisches Klinikum Neunkirchen Gynäkologie und Geburtshilfe, Neunkirchen. 21. Frauenklinik des Universitätsklinikums Ulm, Ulm. 22. Gynäkologische Praxis in der Kreisklinik, Krumbach. 23. Evangelisches Krankenhaus Ludwigsfelde-Teltow, Ludwigsfelde. 24. Marien-Hospital Wesel, Wesel. 25. Frauenklinik am Kreiskrankenhaus Hameln, Hameln. 26. Landkreis Mittweida Krankenhaus gGmbH, Mittweida. 27. Johanniter Krankenhaus Genthin Stendal gGmbH, Stendal. 28. Praxis Dr. Praetz, Bad Mergentheim. 29. Asklepios Paulinen Klinik Wiesbaden, Wiesbaden. 30. Frauenklinik, Städtische Kliniken Esslingen a. N., Esslingen. 31. Frauenklinik Lippe, Lippe. 32. Frauenklinik, Universitätsklinik Halle Wittenberg, Halle. 33. Brustzentrum, Kliniken Essen Mitte, Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen. 34. Kreiskrankenhaus Rendsburg, Rendsburg. 35. Onkologie Bethanien, Frankfurt. 36. Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel. 37. Novartis Pharma GmbH, Nürnberg. 38. Clin-Sol GmbH, Würzburg. 39. Krankenhaus Nordwest, Klinik für Gynäkologie und Gebursthilfe, Frankfurt. 40. Universitätsfrauenklinik Tübingen, Tübingen.
Abstract
Introduction: The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. Material and Methods: Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for various reasons. Results: A total of 4420 patients receiving adjuvant treatment and 252 patients with metastasis receiving palliative treatment were included in the study. For 4181 patients receiving adjuvant treatment, treatment with the aromatase inhibitor letrozole commenced immediately after surgery (upfront). Two hundred patients had initially received tamoxifen and started aromatase inhibitor treatment with letrozole at 1-5 years after diagnosis (switch), und 39 patients only commenced letrozole treatment 5-10 years after diagnosis (extended endocrine therapy). Patient and tumor characteristics were within expected ranges, as were comorbidities and concurrent medication. Conclusion: The data from the EvaluateTM study will offer a good overview of therapy management in the routine care of postmenopausal women with hormone receptor-positive breast cancer. Planned analyses will look at therapy compliance and patient satisfaction with how information is conveyed and the contents of the conveyed information.
Introduction: The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancerpatients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. Material and Methods: Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for various reasons. Results: A total of 4420 patients receiving adjuvant treatment and 252 patients with metastasis receiving palliative treatment were included in the study. For 4181 patients receiving adjuvant treatment, treatment with the aromatase inhibitor letrozole commenced immediately after surgery (upfront). Two hundred patients had initially received tamoxifen and started aromatase inhibitor treatment with letrozole at 1-5 years after diagnosis (switch), und 39 patients only commenced letrozole treatment 5-10 years after diagnosis (extended endocrine therapy). Patient and tumor characteristics were within expected ranges, as were comorbidities and concurrent medication. Conclusion: The data from the EvaluateTM study will offer a good overview of therapy management in the routine care of postmenopausal women with hormone receptor-positive breast cancer. Planned analyses will look at therapy compliance and patient satisfaction with how information is conveyed and the contents of the conveyed information.
Entities:
Keywords:
aromatase inhibitor; breast cancer; compliance; endocrine therapy
Authors: Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias Journal: Lancet Date: 2005 Jan 1-7 Impact factor: 79.321
Authors: P Sinn; S Aulmann; R Wirtz; S Schott; F Marmé; Z Varga; A Lebeau; H Kreipe; A Schneeweiss Journal: Geburtshilfe Frauenheilkd Date: 2013-09 Impact factor: 2.915
Authors: Raimund Jakesz; Richard Greil; Michael Gnant; Marianne Schmid; Werner Kwasny; Ernst Kubista; Brigitte Mlineritsch; Christoph Tausch; Michael Stierer; Friedrich Hofbauer; Karl Renner; Christian Dadak; Ernst Rücklinger; Hellmut Samonigg Journal: J Natl Cancer Inst Date: 2007-12-11 Impact factor: 13.506
Authors: Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: Paul Gaß; Peter A Fasching; Tanja Fehm; Johann de Waal; Mahdi Rezai; Bernd Baier; Gerold Baake; Hans-Christian Kolberg; Martin Guggenberger; Mathias Warm; Nadia Harbeck; Rachel Wuerstlein; Jörg-Uwe Deuker; Peter Dall; Barbara Richter; Grischa Wachsmann; Cosima Brucker; Jan W Siebers; Nikos Fersis; Thomas Kuhn; Christopher Wolf; Hans-Walter Vollert; Georg-Peter Breitbach; Wolfgang Janni; Robert Landthaler; Andreas Kohls; Daniela Rezek; Thomas Noesselt; Gunnar Fischer; Stephan Henschen; Thomas Praetz; Volker Heyl; Thorsten Kühn; Thomas Krauss; Christoph Thomssen; Andre Hohn; Hans Tesch; Christoph Mundhenke; Alexander Hein; Claudia Rauh; Christian M Bayer; Adib Jacob; Katja Schmidt; Erik Belleville; Peyman Hadji; Sara Y Brucker; Matthias W Beckmann; Diethelm Wallwiener; Sherko Kümmel; Christian R Löhberg Journal: Breast Care (Basel) Date: 2016-10-27 Impact factor: 2.860
Authors: C C Hack; P Voiß; S Lange; A E Paul; S Conrad; G J Dobos; M W Beckmann; S Kümmel Journal: Geburtshilfe Frauenheilkd Date: 2015-07 Impact factor: 2.915
Authors: Carolin C Hack; Peter A Fasching; Tanja Fehm; Johann de Waal; Mahdi Rezai; Bernd Baier; Gerold Baake; Hans-Christian Kolberg; Martin Guggenberger; Mathias Warm; Nadia Harbeck; Rachel Wuerstlein; Jörg-Uwe Deuker; Peter Dall; Barbara Richter; Grischa Wachsmann; Cosima Brucker; Jan W Siebers; Nikos Fersis; Thomas Kuhn; Christopher Wolf; Hans-Walter Vollert; Georg-Peter Breitbach; Wolfgang Janni; Robert Landthaler; Andreas Kohls; Daniela Rezek; Thomas Noesslet; Gunnar Fischer; Stefan Henschen; Thomas Praetz; Volker Heyl; Thorsten Kühn; Thomas Krauss; Christoph Thomssen; Andre Hohn; Hans Tesch; Christoph Mundhenke; Alexander Hein; Claudia Rauh; Christian M Bayer; Adib Jacob; Katja Schmidt; Erik Belleville; Peyman Hadji; Sara Y Brucker; Diethelm Wallwiener; Sherko Kümmel; Matthias W Beckmann; Daniela Paepke Journal: Integr Cancer Ther Date: 2016-09-14 Impact factor: 3.279